Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Phase 1

Terminated

Conditions: Anaplastic Thyroid Cancer

Interventions: Drug: CS-7017
Drug: Paclitaxel

First Posted Date: 2008-01-29

Last Posted Date: 2020-09-16

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 19

Registration Number: NCT00603941

Locations: 🇺🇸
Univ of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
Washington University, Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸
Ohio State Univ, Columbus, Ohio, United States

and more 6 locations

Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Stage IV Non-Small Cell Lung Cancer

Interventions: Drug: Paclitaxel
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Vinorelbine Tartrate

First Posted Date: 2008-01-28

Last Posted Date: 2023-09-26

Lead Sponsor: University of Nebraska

Target Recruit Count: 20

Registration Number: NCT00602797

Locations: 🇺🇸
Great Plains Regional Medical Center, North Platte, Nebraska, United States
🇺🇸
CHI Health Saint Francis, Grand Island, Nebraska, United States
🇺🇸
Veterans Administration Medical Center, Omaha, Omaha, Nebraska, United States

and more 2 locations

A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.

Phase 2

Completed

Conditions: Non-Small-Cell Lung Carcinoma
Adenocarcinoma

Interventions: Drug: Bevacizumab
Drug: AG-013736 (axitinib)
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2008-01-25

Last Posted Date: 2013-11-08

Lead Sponsor: Pfizer

Target Recruit Count: 118

Registration Number: NCT00600821

Locations: 🇬🇧
Pfizer Investigational Site, Surrey, United Kingdom

Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology

Phase 3

Terminated

Conditions: Carcinoma, Squamous Cell
Carcinoma, Adenosquamous
Carcinoma, Large Cell
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: CP-751,871 (Figitumumab)
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2008-01-17

Last Posted Date: 2014-01-13

Lead Sponsor: Pfizer

Target Recruit Count: 681

Registration Number: NCT00596830

Locations: 🇺🇦
Pfizer Investigational Site, Sumy, Ukraine

Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: cyclophosphamide
Drug: carboplatin
Drug: doxorubicin hydrochloride
Drug: paclitaxel

First Posted Date: 2008-01-09

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Centre, Singapore

Target Recruit Count: 16

Registration Number: NCT00589238

Locations: 🇸🇬
National Cancer Centre - Singapore, Singapore, Singapore
🇸🇬
KK Women's and Children Hospital, Singapore, Singapore

A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer

Phase 2

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Lovastatin

First Posted Date: 2008-01-02

Last Posted Date: 2018-01-05

Lead Sponsor: University of Iowa

Target Recruit Count: 11

Registration Number: NCT00585052

Locations: 🇺🇸
Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Paclitaxel
Biological: Mapatumumab
Drug: Carboplatin

First Posted Date: 2007-12-31

Last Posted Date: 2013-08-08

Lead Sponsor: Human Genome Sciences Inc.

Target Recruit Count: 111

Registration Number: NCT00583830

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States
🇩🇪
Klinikum der Johannes-Gutenberg-Universität Mainz, Mainz, Germany

and more 30 locations

Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: celecoxib
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiation Therapy

First Posted Date: 2007-12-28

Last Posted Date: 2013-04-25

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 30

Registration Number: NCT00581971

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

Optimized Intensity Modulated Irradiation for Head and Neck Cancer

Not Applicable

Completed

Conditions: Head and Neck Cancer

Interventions: Radiation: IMRT
Drug: Paclitaxel
Drug: Carboplatin
Drug: Cisplatin
Drug: 5-Fluorouracil

First Posted Date: 2007-12-27

Last Posted Date: 2016-09-07

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 90

Registration Number: NCT00580983

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: cisplatin
Drug: bevacizumab
Drug: doxorubicin
Drug: cyclophosphamide
Drug: paclitaxel

First Posted Date: 2007-12-24

Last Posted Date: 2021-05-26

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 51

Registration Number: NCT00580333

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy